Paul Berns and Laura Deming
February 8, 2022 05:00 AM ESTUpdated 06:50 AM
Startups

Ex­clu­sive: ARCH-backed ex­er­cise-in-a-pill start­up qui­et­ly laid off half its staff, ‘ful­ly piv­ot­ed’ in Oc­to­ber

Jason Mast

Editor

In De­cem­ber 2019, a tiny decade-old Cal­i­for­nia start­up known as Cardero Ther­a­peu­tics an­nounced a new name — Epir­i­um Bio — a new di­rec­tion and $85 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times